Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: Development and characterization of a novel bispecific antibody

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 51-62

  Fischer, Jens A A ^a   Hueber, Axel J ^b   Wilson, Stacy ^c   Galm, Margarete ^a   Baum, Wolfgang ^b   Kitson, Christopher ^c,d   Auer, Johannes ^a   Lorenz, Stefan H ^a   Moelleken, Jörg ^a   Bader, Martin ^a   Tissot, Alain C ^a   Tan, Seng Lai ^c,e   Seeber, Stefan ^a   Schett, Georg ^b  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Roche Pharmaceutical Research and Early Development   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e EMD Serono Research Institute Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; METALLOPROTEINASE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; FIBROBLAST CULTURE; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MESENCHYME CELL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; FIBROBLAST; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; SYNOVIUM; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FIBROBLASTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-17; INTERLEUKIN-8; METALLOPROTEASES; MICE; MICE, TRANSGENIC; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919904195     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38896     Document Type: Article

References (46)

1. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Firestein GS,. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004; 114: 471-4.
3. Firestein GS,. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005; 11: S39-44.
4. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
5. Smolen JS, Maini RN,. Interleukin-6: a new therapeutic target [published erratum appears in Arthritis Res Ther 2006;8:407]. Arthritis Res Ther 2006; 8 Suppl 2: S5.
6. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
7. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228-34.
8. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-9.
9. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184: 3336-40.
10. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-82.
11. Van den Berg WB, Miossec P,. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 549-53.
12. Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012; 39: 1185-91.
13. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72: 863-9.
14. Tak PP, Durez P, Gomez-Reino JJ, Wittmer B, Chindalore V, DiPadova F, et al. AIN457 shows a good safety profile and clinical benefit in patients with active rheumatoid arthritis (RA) despite methotrexate therapy: 16-weeks results from a randomized proof-of-concept trial [abstract]. Arthritis Rheum 2009; 60 Suppl: S717.
15. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156-63.
16. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
18. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108: 11187-92.
19. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005; 128: 376-92.
20. Qi J, Kan F, Ye X, Guo M, Zhang Y, Ren G, et al. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis. Int Immunopharmacol 2012; 14: 770-8.
21. Zhang Y, Ren G, Guo M, Ye X, Zhao J, Xu L, et al. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol 2013; 15: 199-205.
22. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M,. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7.
23. Husby G, Williams RC Jr., Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-71.
24. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
25. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA,. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5.
26. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164: 2832-8.
27. Katz Y, Nadiv O, Beer Y,. Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum 2001; 44: 2176-84.
28. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis 2007; 13: 1323-32.
29. Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J,. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 1995; 7: 759-70.
30. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8.
31. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ,. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-11.
32. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-31.
33. Hot A, Lenief V, Miossec P,. Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 2012; 71: 768-76.
34. Hot A, Lavocat F, Lenief V, Miossec P,. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheum Dis 2013; 72: 754-60.
35. Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, et al. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFα. Arthritis Res Ther 2008; 10: R47.
36. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM,. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-κB but not C/EBPβ or c-Jun. J Immunol 2000; 165: 7199-206.
37. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6: R120-8.
38. Yamana J, Morand EF, Manabu T, Sunahori K, Takasugi K, Makino H, et al. Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. Cell Immunol 2012; 272: 293-8.
39. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y,. Synergism between tumor necrosis factor α and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009; 46: 1854-9.
40. Hot A, Zrioual S, Lenief V, Miossec P,. IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes. Ann Rheum Dis 2012; 71: 1393-401.
41. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N,. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001; 167: 5381-5.
42. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, FitzGerald O, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, oncostatin M and response to biologic therapies. Arthritis Res Ther 2009; 11: R113.
43. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011; 63: 2329-39.
44. Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, Heiland GR, et al. Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol 2012; 42: 413-23.
45. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J,. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251-9.
46. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71: 1741-8.